Acasă › Limfom Burkitt › Colorado
Studii clinice pentru Limfom Burkitt în Colorado
13 studii pentru Limfom Burkitt caută participanți în Colorado.
Orașe în Colorado
Text oficial al studiului (în engleză)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Colorado, Aurora
În curs de recrutareFaza 2
366 Days – 46 Years · Toate sexele · Actualizat 2 oct. 2026 · NCT06124157Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
În curs de recrutareStudiu observațional
Vârste de la 0 la 38 · Toate sexele · Actualizat 1 oct. 2026 · NCT06131801Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital Colorado, Aurora
În curs de recrutareFaza 2
365 Days · Toate sexele · Actualizat 25 sept. 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- CBCI, Colorado Blood Cancer Institute, Denver
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 21 sept. 2026 · NCT07648264Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora
În curs de recrutareFaza 1/2
6 Months – 25 Years · Toate sexele · Actualizat 17 sept. 2026 · NCT06395103UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
- Children's Hospital Colorado, Aurora
În curs de recrutareFaza 1/2
31 Days – 30 Years · Toate sexele · Actualizat 14 sept. 2026 · NCT04544592A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Colorado, Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
În curs de recrutareFaza 2
Vârste de la 1 la 30 · Toate sexele · Actualizat 1 sept. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital Colorado, Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
În curs de recrutareFaza 3
365 Days – 25 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Colorado Children's Hospital, Denver
În curs de recrutareFaza 2
Vârste de la 7 la 25 · Toate sexele · Actualizat 19 aug. 2026 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Colorado Blood Cancer Institute, Denver
În curs de recrutareFaza 1/2
Vârste de la 13 la 90 · Toate sexele · Actualizat 6 aug. 2026 · NCT06533579CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
- Children's Hospital Colorado, Aurora
În curs de recrutareFaza 1
3 Months – 30 Years · Toate sexele · Actualizat 28 nov. 2025 · NCT06559189Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- University of Colorado - Aurora Cancer Center, Aurora
- Sarah Cannon - Colorado Blood Cancer Institute, Denver
În curs de recrutareFaza 1/2
Vârste de la 15 la 50 · Toate sexele · Actualizat 9 sept. 2025 · NCT04150497The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's Hospital Colorado, Aurora
În curs de recrutareFaza 2
Vârste de la 1 la 25 · Toate sexele · Actualizat 4 mai 2025 · NCT03509961Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.